Summit Therapeutics Posts Wider Loss In Q3

October 20, 2025 — 07:15 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Summit Therapeutics Inc. (SMMT) posted a GAAP net loss in the third quarter of $231.8 million or $0.31 per share, compared to a loss of $56.3 million or $0.08 per share, a year ago. Non-GAAP net loss in the third quarter was $101.0 million or $0.13 per compared to a loss of $36.9 million or $0.05 per share, prior year.

Summit also announced that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application in order to seek approval for ivonescimab plus chemotherapy. The company intends to submit the BLA in the fourth quarter of 2025. Summit also announced its intention to expand its ivonescimab clinical development program with an additional set of Phase III clinical studies.

Shares of Summit are down 5% in pre-market trade on Monday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Summit Therapeutics Posts Wider Loss In Q3

Tags

Latest Articles